Head-to-head · WeighScore
Kongo vs Piper
The verdict
Kongo takes it — 83.8/100 to 81.9/100, but only just.
Kongo grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Cheap semaglutide ($119) but a steeper tirzepatide step-up ($229); verified, nationwide. Piper is close behind and may still be the better fit — see the factor split below.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Kongo | Piper |
|---|---|---|
| WeighScore | 83.8/100 | 81.9/100 |
| Grade | B | B− |
| Site position | #19 | #31 |
| Semaglutide | $119/mo | $135/mo |
| Tirzepatide | $229/mo | $199/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Site position #19 · B
Strengths
- $119 semaglutide
- All 50 states, LegitScript-verified
- Both molecules
Where it loses points
- Tirzepatide jumps to $229/mo
- Injection-only
- Monitoring detail sparse
Site position #31 · B−
Strengths
- $135 sema / $199 tirz
- All 50 states
- Both molecules
Where it loses points
- Independent LegitScript certification has not been verified for this review
- Injection-only
- Monitoring detail limited
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). CoreAge Rx advertises flat dose pricing for compounded injections, with no membership fee; its consultation-fee and refund deadlines deserve a close read before paying.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.